Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus

被引:92
作者
Wong, CK
Lit, LCW
Tam, LS
Li, EK
Lam, CWK [1 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
关键词
SLE; osteopontin; IL-18; SLEDAI;
D O I
10.1093/rheumatology/keh558
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Osteopontin (OPN) is an extracellular matrix cell adhesion phosphoprotein with immunological activities including stimulation of macrophage chemotaxis, T-helper type 1 lymphocyte response and B-cell antibody synthesis. Overexpression of OPN has been associated with the development of the autoimmune/lymphoproliferative syndrome. Methods. We measured the plasma concentration and ex vivo production of OPN, and the plasma proinflammatory IL-18 concentration in 54 SLE patients with or without renal impairment (RSLE group and SLE group, respectively) and 26 sex- and age-matched control (NC) subjects using an enzyme-linked immunoabsorbent assay. Results. Plasma OPN concentrations were significantly higher in RSLE and SLE patients than in the NC group (both P < 0.001). Increase in OPN concentration correlated positively and significantly with SLEDAI score in all SLE patients (r = 0.308, P = 0.023). The ex vivo production of OPN upon mitogen activation of peripheral blood mononuclear cells was significantly higher in the RSLE and SLE groups than in the NC group (both P < 0.001). In RSLE patients, plasma OPN concentration showed a significant positive correlation with proinflammatory cytokine IL-18 concentration (r = 0.404, P = 0.037). Conclusion. The above results suggest that the production of OPN is associated with the inflammatory process and SLE development, and may serve as a potential disease marker of SLE.
引用
收藏
页码:602 / 606
页数:5
相关论文
共 39 条
[1]  
Akahoshi M, 1999, ARTHRITIS RHEUM, V42, P1644, DOI 10.1002/1529-0131(199908)42:8<1644::AID-ANR12>3.0.CO
[2]  
2-L
[3]   CYTOKINE PROFILE IN SYSTEMIC LUPUS-ERYTHEMATOSUS, RHEUMATOID-ARTHRITIS, AND OTHER RHEUMATIC DISEASES [J].
ALJANADI, M ;
ALBALLA, S ;
ALDALAAN, A ;
RAZIUDDIN, S .
JOURNAL OF CLINICAL IMMUNOLOGY, 1993, 13 (01) :58-67
[4]   Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention [J].
Aringer, M ;
Smolen, J .
LUPUS, 2004, 13 (05) :344-347
[5]   Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity [J].
Ashkar, S ;
Weber, GF ;
Panoutsakopoulou, V ;
Sanchirico, ME ;
Jansson, M ;
Zawaideh, S ;
Rittling, SR ;
Denhardt, DT ;
Glimcher, MJ ;
Cantor, H .
SCIENCE, 2000, 287 (5454) :860-864
[6]  
BAUTISTA DS, 1994, J BIOL CHEM, V269, P23280
[7]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[8]   The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease [J].
Chabas, D ;
Baranzini, SE ;
Mitchell, D ;
Bernard, CCA ;
Rittling, SR ;
Denhardt, DT ;
Sobel, RA ;
Lock, C ;
Karpuj, M ;
Pedotti, R ;
Heller, R ;
Oksenberg, JR ;
Steinman, L .
SCIENCE, 2001, 294 (5547) :1731-1735
[9]   High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation [J].
Chiocchetti, A ;
Indelicato, M ;
Bensi, T ;
Mesturini, R ;
Giordano, M ;
Sametti, S ;
Castelli, L ;
Bottarel, F ;
Mazzarino, MC ;
Garbarini, L ;
Giacopelli, F ;
Valesini, G ;
Santoro, C ;
Dianzani, I ;
Ramenghi, U ;
Dianzani, U .
BLOOD, 2004, 103 (04) :1376-1382
[10]   Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease acitivity in systemic lupus erythematosus [J].
Davas, EM ;
Tsirogianni, A ;
Kappou, I ;
Karamitsos, D ;
Economidou, I ;
Dantis, PC .
CLINICAL RHEUMATOLOGY, 1999, 18 (01) :17-22